You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

MACUGEN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Macugen, and what generic alternatives are available?

Macugen is a drug marketed by Bausch And Lomb Inc and is included in one NDA.

The generic ingredient in MACUGEN is pegaptanib sodium. Additional details are available on the pegaptanib sodium profile page.

Drug patent expirations by year for MACUGEN
Drug Prices for MACUGEN

See drug prices for MACUGEN

Recent Clinical Trials for MACUGEN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Oslo University HospitalPhase 4
Retina Vitreous Associates of FloridaN/A
Vision Research FoundationPhase 2

See all MACUGEN clinical trials

US Patents and Regulatory Information for MACUGEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb Inc MACUGEN pegaptanib sodium INJECTABLE;INTRAVITREAL 021756-001 Dec 17, 2004 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for MACUGEN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch And Lomb Inc MACUGEN pegaptanib sodium INJECTABLE;INTRAVITREAL 021756-001 Dec 17, 2004 ⤷  Try a Trial ⤷  Try a Trial
Bausch And Lomb Inc MACUGEN pegaptanib sodium INJECTABLE;INTRAVITREAL 021756-001 Dec 17, 2004 ⤷  Try a Trial ⤷  Try a Trial
Bausch And Lomb Inc MACUGEN pegaptanib sodium INJECTABLE;INTRAVITREAL 021756-001 Dec 17, 2004 ⤷  Try a Trial ⤷  Try a Trial
Bausch And Lomb Inc MACUGEN pegaptanib sodium INJECTABLE;INTRAVITREAL 021756-001 Dec 17, 2004 ⤷  Try a Trial ⤷  Try a Trial
Bausch And Lomb Inc MACUGEN pegaptanib sodium INJECTABLE;INTRAVITREAL 021756-001 Dec 17, 2004 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for MACUGEN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0957929 PA2006004,C0957929 Lithuania ⤷  Try a Trial PRODUCT NAME: PEGAPTANIBUM; REGISTRATION NO/DATE: EU/1/05/325/001 20060131
0957929 PA2006004 Lithuania ⤷  Try a Trial PRODUCT NAME: PEGAPTANIBUM; REG. NO/DATE: EU/1/05/325/001 20060131
0957929 300234 Netherlands ⤷  Try a Trial 300234, 20171017, EXPIRES: 20210130
0957929 SPC024/2006 Ireland ⤷  Try a Trial SPC024/2006:, EXPIRES: 20210130
0957929 C00957929/01 Switzerland ⤷  Try a Trial PRODUCT NAME: PEGAPTANIB; REGISTRATION NUMBER/DATE: SWISSMEDIC 57459 15.02.2006
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.